Roche‘s Boulder plant, engaged in the production of therapeutic peptide compounds, is equipped with large scale synthetic manufacturing technologies.
The agreement allows ICIG to take over the technical development and small molecule manufacturing capabilities of Roche’s affiliate.
Following the acquisition, Roche’s Boulder site will be re branded as Corden Pharma Colorado, as part of its pharmaceutical business within the Corden Pharma organization.
Roche Chemical Manufacturing head Georg Wiebecke said selling the Boulder site to ICIG will secure a reliable supplier to meet Roche’s demand for commercial scale peptides and other medicinal compounds.